<DOC>
	<DOCNO>NCT00479557</DOCNO>
	<brief_summary>To assess safety , tolerability , immunogenicity ACC-001 , investigational active immunization , patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Diagnosis probable Alzheimer 's Disease MiniMental State Examination ( MMSE ) score 1626 ( except Germany : 2126 ) Brain MRI consistent Alzheimer Disease Concurent use Chloniesterase inhibitor memantine allow stable Other inclusion criterion apply Significant Neurological Disease Alzheimer 's disease Major psychiatric disorder Contraindication undergo brain MRI Clinically significant systemic illness Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>active immunization</keyword>
</DOC>